Sugi Predict

Sugi Predict / Compounds / SCHEMBL1180883

SCHEMBL1180883

SCHEMBL1180883

COCOc1ccc(C(C)=O)c(O)c1

nearest known ligand 0.67

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.67
▸ CYP3A4 P08684 1/20 0.67
▸ HPGD P15428 1/20 0.67
▸ MAPK1 P28482 1/20 0.67
▸ MAOB P27338 17/20 0.63
▸ MAOA P21397 6/20 0.60
▸ PPARD Q03181 1/20 0.58
▸ MAPT P10636 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24474194 0.87 MAOB (0.58) ALDH1A1CYP3A4HPGDMAPK1MAOB
SCHEMBL31254034 0.86 PPARD (0.59) ALDH1A1CYP3A4HPGDMAPK1MAOB
SCHEMBL4121168 0.85 CA12 (0.62) ALDH1A1CYP3A4HPGDMAPK1MAOB
SCHEMBL3210641 0.85 MAOB (0.65) ALDH1A1CYP3A4HPGDMAPK1MAOB
SCHEMBL5445458 0.85 KDM4E (0.49) ALDH1A1CYP3A4HPGDMAPK1MAOB
SCHEMBL31088170 0.85 KDM4E (0.49) ALDH1A1CYP3A4HPGDMAPK1MAOB
SCHEMBL7521761 0.84 HSP90AB1 (0.60) ALDH1A1CYP3A4HPGDMAPK1MAOB
SCHEMBL13741732 0.83 ALDH1A1 (0.45) ALDH1A1CYP3A4HPGDMAPK1MAOB
SCHEMBL429049 0.83 MAOB (0.67) ALDH1A1CYP3A4HPGDMAPK1MAOB
SCHEMBL12047255 0.83 ALDH1A1 (0.58) ALDH1A1CYP3A4HPGDMAPK1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20250134146-A1 FLAVANONE COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS FIRMENICH INCORPORATED (US) 2025-05-01 — — US disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
EP-2247558-B2 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION LILLY CO ELI (US) 2024-07-03 — — EP disclosed
US-11964989-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2024-04-23 — — US disclosed
CN-114615981-B KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2024-04-12 — — CN disclosed
US-20230099567-A1 COMPOSITION FOR TREATMENT, PREVENTION, OR AMELIORATION OF LYMPHEDEMA RAPPELER CO., LTD. (KR) 2023-03-30 — — US disclosed
US-20230077225-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. 2023-03-09 — — US disclosed
US-11453683-B1 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2022-09-27 — — US disclosed
EP-4021444-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-07-06 — — EP disclosed
US-20100272656-A1 Flavor Molecules GIVAUDAN SA (CH) 2010-10-28 — — US disclosed
US-20100099755-A1 CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF PURDUE RESEARCH FOUNDATION (US) 2010-04-22 — — US disclosed
US-20100040753-A1 FLAVOR MOLECULES GIVAUDAN SA (CH) 2010-02-18 — — US disclosed
WO-2009105906-A1 FLAVOR MOLECULES GIVAUDAN SA (CH) 2009-09-03 — — WO disclosed
WO-2009102498-A1 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2009-08-20 — — WO disclosed
WO-2008076767-A1 CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF PURDUE RESEARCH FOUNDATION (US) 2008-06-26 — — WO disclosed
WO-2008076767-A1 CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF PURDUE RESEARCH FOUNDATION (US) 2008-06-26 — — WO disclosed
US-5234951-A Anti-ulcer agent comprising chalcone derivative TSUMURA JUNTENDO, INC. (JP) 1993-08-10 — — US disclosed
US-5106871-A Reduced side effects TSUMURA & CO. (JP) 1992-04-21 — — US disclosed
EP-0292576-A1 ANTI-ULCEROUS AGENT CONTAINING CHALCONE DERIVATIVE AS EFFECTIVE INGREDIENT AND NOVEL CHALCONE DERIVATIVES TSUMURA & CO. (JP) 1988-11-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230077225-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS ALDH1A1 2681/4885CYP3A4 3974/4885HPGD 749/4885
US-20100099755-A1 CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF NRAS, FAU, DPYD ALDH1A1 2572/4885CYP3A4 46/4885HPGD 294/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS ALDH1A1 1816/4885CYP3A4 4044/4885HPGD 968/4885
US-20100272656-A1 Flavor Molecules TAS2R30, TAS2R31, TAS2R1 ALDH1A1 683/4885CYP3A4 1261/4885HPGD 1002/4885
US-20100040753-A1 FLAVOR MOLECULES TAS2R30, TAS2R31, TAS2R1 ALDH1A1 683/4885CYP3A4 1261/4885HPGD 1002/4885
US-20230099567-A1 COMPOSITION FOR TREATMENT, PREVENTION, OR AMELIORATION OF LYMPHEDEMA LIPG, LPL, LTA ALDH1A1 768/4885CYP3A4 4015/4885HPGD 347/4885
US-11964989-B2 KRas G12D inhibitors KRAS, NRAS, HRAS ALDH1A1 1957/4885CYP3A4 4280/4885HPGD 823/4885
US-11453683-B1 KRas G12D inhibitors KRAS, NRAS, HRAS ALDH1A1 2055/4885CYP3A4 4362/4885HPGD 864/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS ALDH1A1 2681/4885CYP3A4 3974/4885HPGD 749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.